BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy · 02 Jul 2026
FDA Scientists Advise Against Peptide Compounding Access as PCAC Panel Composition Draws Scrutiny — What It Means for the July 23-24 Review
With three weeks to go before the FDA's Pharmacy Compounding Advisory Committee meets to review seven peptides including Semax, Emideltide, BPC-157, and MOTS-c, FDA career scientists have publicly recommended against easing compounding restrictions — placing agency staff in direct tension with HHS Secretary Kennedy's stated position. Simultaneously, scrutiny of the panel's composition has intensified after it emerged that several members have financial ties to the peptide industry.
Read briefing →
Research Pipeline
KPV: The Alpha-MSH Tripeptide With a 20-Year Preclinical Record Now Facing Its First Formal FDA Compounding Review
KPV (Lys-Pro-Val) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with roughly two decades of preclinical data on gut and skin inflammation — but no completed human clinical trials. The FDA's Pharmacy Compounding Advisory Committee will review it for the 503A Bulk Drug Substances List on 23 July 2026, the most significant regulatory event in its history. Here is what the evidence shows and what the outcome may mean for research procurement in the UK and US.
01 Jul 2026
Research Pipeline
BPC-157: The Gastric Peptide With 100+ Preclinical Studies and Near-Zero Human Trial Data — What the July PCAC Review and MHRA Scrutiny Mean for Research Procurement
BPC-157 is arguably the most discussed peptide in the current FDA regulatory cycle, yet its human evidence base remains strikingly thin. With a PCAC advisory vote scheduled for 23–24 July 2026 and the MHRA having opened a separate investigation into UK clinics making claims about the compound, research-procurement professionals need a clear-eyed picture of where the science, the regulation, and the supply chain actually stand.
30 Jun 2026
Regulatory & Policy
FDA's 503B Bulks List Proposal: What Today's Comment Deadline Means for GLP-1 Peptide Compounding
Today, 29 June 2026, marks the close of the FDA's public comment period on its proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility Bulks List. If finalised, the rule would permanently bar large-scale bulk compounding of these three GLP-1 agents — regardless of future market conditions. UK research procurement teams and supply-chain professionals should understand what the 503B framework is, how the proposal sits alongside the parallel PCAC…
29 Jun 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide at the Centre of the July 2026 PCAC Review — What the Evidence and Regulatory Shift Mean for Research Procurement
Epitalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide derived from pineal gland research, is among the seven compounds scheduled for formal FDA Pharmacy Compounding Advisory Committee review on 24 July 2026. With removal from Category 2 confirmed in April and written comments to the docket due by 9 July, UK research procurement teams need a clear-eyed account of its evidence base, remaining regulatory unknowns, and the supply-chain pressures now bearing on peptide API sourcing.
28 Jun 2026
Research Pipeline
MOTS-c: The Mitochondrial-Derived Peptide Facing Its First Major Regulatory Reckoning at the July 2026 PCAC
MOTS-c — a 16-amino-acid peptide encoded by the mitochondrial genome — is scheduled for FDA Pharmacy Compounding Advisory Committee review on 23 July 2026, making it one of the more scientifically distinctive compounds on the Day-One agenda. This briefing covers its mechanism, the state of clinical evidence, its WADA prohibition, current regulatory grey-zone status, and what the PCAC outcome means for UK research procurement teams.
27 Jun 2026
Research Pipeline
Selank: The Tuftsin-Derived Anxiolytic Peptide Absent from the July PCAC — What the Regulatory Grey Zone Means for Research Procurement
Selank is a synthetic heptapeptide with Russian clinical approval for generalised anxiety disorder and one of the better-documented evidence bases among research peptides. Yet it carries no July 2026 PCAC slot, no FDA-authorised compounding pathway, and sits in a regulatory grey zone that procurement teams must understand before sourcing.
26 Jun 2026
Research Pipeline
Retatrutide: What the TRIUMPH-1 Phase 3 Data and NDA Timeline Mean for Peptide Research Procurement
Eli Lilly's triple-agonist retatrutide posted a 28.3% average weight loss at 80 weeks in the Phase 3 TRIUMPH-1 trial — the largest efficacy signal ever recorded in a randomised obesity study. With an NDA submission targeted for Q4 2026 and a grey market already active, procurement teams need to understand what the compound is, where it stands legally, and how to source it responsibly for legitimate research.
25 Jun 2026
Research Pipeline
TB-500: What a June 2026 Scoping Review and the July PCAC Agenda Mean for Research Procurement
A peer-reviewed scoping review published on 19 June 2026 maps the TB-500 and thymosin beta-4 evidence base and finds the human clinical literature remains sparse. Combined with the peptide's inclusion on the FDA PCAC Day 1 agenda for 23 July 2026 and its continued prohibition under the 2026 WADA Prohibited List, procurement teams face a layered due-diligence picture that is more complex than the compound's popularity suggests.
24 Jun 2026
Industry & Community
The Oral Peptide Race: How 2026's Approvals and Investment Wave Are Reshaping Peptide Drug Development
Two landmark FDA approvals in early 2026 — Eli Lilly's orforglipron (Foundayo) and Johnson & Johnson's icotrokinra (ICOTYDE) — have validated oral peptide and peptide-mimetic delivery as a commercially viable drug class. Backed by hundreds of millions in fresh venture capital, the sector is moving rapidly from injectable-only paradigms toward once-daily pills. For UK research-procurement teams, the shift has direct implications for the tools, reference compounds, and analytical standards their…
23 Jun 2026
Research Pipeline
Thymosin Alpha-1: The Internationally Approved Immune Peptide in Regulatory Limbo — What the PCAC Vote and Category 2 Removal Mean for Research Procurement
Thymosin alpha-1 is the most clinically validated immune-modulating peptide in the research catalogue — approved as Zadaxin in over 35 countries and evaluated in more than 80 clinical trials. Yet in the United States it remains without FDA approval, was removed from Category 2 in September 2024, and was voted down 4-17 by the PCAC in December 2024. It is not scheduled for the July 2026 PCAC meeting. This briefing examines what that regulatory history means for UK research procurement in…
22 Jun 2026
Research Pipeline
CJC-1295 and Ipamorelin: The Growth Hormone Pair Left Out of the July 2026 PCAC — What the Regulatory Limbo Means for Research Procurement
CJC-1295 and Ipamorelin are among the most widely studied growth hormone secretagogue peptides, yet they occupy a regulatory position distinct from the twelve substances currently heading for the July 2026 PCAC review. A 2024 advisory committee already voted against their inclusion on the 503A Bulks List, and neither compound appears on either scheduled PCAC agenda. Research procurement teams need to understand what that means for legitimate sourcing and laboratory use.
21 Jun 2026